Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23938306 | 0.84 | PNMT (0.37) | SLC6A4HRH3SRD5A1KCNH2 | |
| SCHEMBL18252819 | 0.82 | KCNH2 (0.44) | HRH3SRD5A1KCNH2 | |
| SCHEMBL20013725 | 0.82 | KCNH2 (0.37) | SLC6A4HRH3SRD5A1KCNH2 | |
| SCHEMBL18255846 | 0.81 | SRD5A1 (0.42) | SLC6A4HRH3SRD5A1SLC6A2SLC6A3 | |
| SCHEMBL18255842 | 0.81 | SRD5A1 (0.42) | SLC6A4HRH3SRD5A1SLC6A2SLC6A3 | |
| SCHEMBL23938293 | 0.81 | SLC6A4 (0.43) | SLC6A4HRH3SRD5A1SLC6A2SLC6A3 | |
| SCHEMBL18255844 | 0.81 | SRD5A1 (0.42) | SLC6A4HRH3SRD5A1SLC6A2SLC6A3 | |
| SCHEMBL18254950 | 0.81 | SLC6A4 (0.44) | SLC6A4HRH3SRD5A1SLC6A2SLC6A3 | |
| SCHEMBL5249380 | 0.75 | SLC6A4 (0.69) | SLC6A4HRH3SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10954592 | 0.74 | SLC6A4 (0.41) | SLC6A4HRH3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2019136368-A2 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019060820-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A4 4017/4885HRH3 802/4885SRD5A1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.